WallStreetZenWallStreetZen

NASDAQ: RLYB
Rallybio Corp Stock Forecast, Predictions & Price Target

Analyst price target for RLYB

Based on 5 analysts offering 12 month price targets for Rallybio Corp.
Min Forecast
$1.50-23.86%
Avg Forecast
$9.90+402.54%
Max Forecast
$15.00+661.42%

Should I buy or sell RLYB stock?

Based on 5 analysts offering ratings for Rallybio Corp.
Buy
Strong Buy
0 analysts 0%
Buy
4 analysts 80%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RLYB stock forecasts and price targets.

RLYB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-07
lockedlocked$00.00+00.00%2024-02-07
lockedlocked$00.00+00.00%2024-02-07
lockedlocked$00.00+00.00%2024-02-07
lockedlocked$00.00+00.00%2023-12-21

1 of 1

Forecast return on equity

Is RLYB forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.53%

Forecast return on assets

Is RLYB forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

RLYB revenue forecast

What is RLYB's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$8.3M
Avg 2 year Forecast
$67.5M
Avg 3 year Forecast
$210.0M

RLYB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RLYB$1.97$9.90+402.54%Buy
ANEB$2.87$6.67+132.30%Strong Buy
GNTA$4.10N/AN/A
ALGS$0.99N/AN/A
KZR$1.02$11.00+978.43%Buy

Rallybio Stock Forecast FAQ

Is Rallybio Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: RLYB) stock is to Buy RLYB stock.

Out of 5 analysts, 0 (0%) are recommending RLYB as a Strong Buy, 4 (80%) are recommending RLYB as a Buy, 1 (20%) are recommending RLYB as a Hold, 0 (0%) are recommending RLYB as a Sell, and 0 (0%) are recommending RLYB as a Strong Sell.

If you're new to stock investing, here's how to buy Rallybio stock.

What is RLYB's revenue growth forecast for 2027-2029?

(NASDAQ: RLYB) Rallybio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.

Rallybio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RLYB's revenue for 2027 to be $314,065,689, with the lowest RLYB revenue forecast at $314,065,689, and the highest RLYB revenue forecast at $314,065,689. On average, 1 Wall Street analysts forecast RLYB's revenue for 2028 to be $2,551,453,025, with the lowest RLYB revenue forecast at $2,551,453,025, and the highest RLYB revenue forecast at $2,551,453,025.

In 2029, RLYB is forecast to generate $7,937,055,987 in revenue, with the lowest revenue forecast at $7,937,055,987 and the highest revenue forecast at $7,937,055,987.

What is RLYB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RLYB) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is RLYB's Price Target?

According to 5 Wall Street analysts that have issued a 1 year RLYB price target, the average RLYB price target is $9.90, with the highest RLYB stock price forecast at $15.00 and the lowest RLYB stock price forecast at $1.50.

On average, Wall Street analysts predict that Rallybio's share price could reach $9.90 by Feb 7, 2025. The average Rallybio stock price prediction forecasts a potential upside of 402.54% from the current RLYB share price of $1.97.

What is RLYB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RLYB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.